Most oncological pancreas resections must consider the mesopancreas
These important findings clearly show underestimated tumor extensions into the mesopancreas even in localized, primary resectable PDAC patients who are currently amenable for upfront resection. Synergistically to total mesorectal or mesocolic excision, which is applied to all stages of colorectal disease, MPE is justified in primary resectable patients as well. Therefore, MPE should be employed in all PDAC patients. Since the infiltration status of the mesopancreas was a significant factor for incomplete resection in primary resectable PDAC patients, neoadjuvant treatment options for must be discussed.
Authors
- Tom Luedde (ORCID: https://orcid.org/0000-0002-6288-8821)
- Sami Alexander Safi (ORCID: https://orcid.org/0000-0002-9874-9225)
- Steven David (ORCID: https://orcid.org/0000-0001-6370-5233)
- Christoph Roderburg (ORCID: https://orcid.org/0000-0002-1409-7697)
- Iréne Esposito (ORCID: https://orcid.org/0000-0002-0554-2402)
- Wolfram Trudo Knoefel (ORCID: https://orcid.org/0000-0003-2472-8314)
- Georg Fluegen (ORCID: https://orcid.org/0000-0002-9322-1659)
- Sascha Vaghiri
- Lena Häberle (ORCID: https://orcid.org/0000-0002-8793-568X)
Institutions
- Düsseldorf University Hospital (DE)
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1186/s12885-025-13599-x
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05